Skip to content

Research areas and technologies

Orion’s pharmaceutical R&D focuses on pain and oncology. Orion also develops veterinary and generic drugs. 


Orion oncology develops novel proprietary drugs for the treatment of cancer. Orion’s oncology research and development has a long history with top expert professionals in the field. The first proprietary drug has been on market for breast cancer already since 1988. The latest innovation for the treatment of prostate cancer got marketing authorization in the U.S in 2019 and in Europe 2020. 


Pain is one of the most common reasons why people use healthcare services. Orion is working to find new types of painkillers and pain treatments for patients suffering from acute or chronic pain. The goal is to develop more effective, safer and non-addictive medicines that can fill the gaps in existing treatment options. Orion is studying several prospective non-opioid treatments.  

Neurological disorders medicines

Orion has a long track record in developing new medicine for the treatment of neurological diseases. As a result of these research projects new medicines for the treatment of Parkinson’s disease have been developed.

Animal health

Orion’s innovative veterinary product development has a long history. In addition, our human drug and formulation innovations are utilised when new therapies and treatment methods are being developed for animals.

Generic drugs

Orion also develops and co-develops new generic medicinal substances in collaboration with its partners. A generic drug is a drug that contains the same active pharmaceutical ingredient as a corresponding proprietary product that no longer has patent protection. 

The development of generic drugs is more simple and economical than the development of proprietary drugs since the necessary studies on the active ingredient have already been carried out. The development of generics usually takes two to three years.